Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
received:
19
05
2024
accepted:
22
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
14
8
2024
Statut:
aheadofprint
Résumé
Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers. A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy. Three validate 4-items measures were used: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM). Out of 61 ICONA centres, 38 (62%) completed the survey: 57.9% were academic centres, 42.1% were hospital-based. In total, 104 respondents were ID physicians (57.4%), 77 were nurses (42.5%); 4.5% of all PWH followed at the 38 centres started LAI CAB/RPV at time of study. Centres taking care of >1000 PWH reported 95% application of procedures for LA implementation, higher than other centres (P = 0.009). Mean score of AIM was (16.0, standard deviation, SD, 3.3), of IAM (16.0, SD 3.0) and FIM (16.0, SD 2.9). A linear correlation was found between AIM and the number of people with HIV who started LAI CAB/RPV (25-50 versus <25, coefficient of correlation [b] 2.57, 95%CI 0.91-4.60, P = 0.004), academic versus hospital-based centres (b -1.59, 95%CI -2.76-0.110044, P = 0.007) and the absence of preliminary systematic assessment of staff (b -1.98, 95%CI -3.31-0.65, P = 0.004). Implementation barriers were not significantly different according to the number of PWH/centre. LAI CAB/RPV implementation was low, with a great variability according to centre size. Tailored and centre-specific interventions to address barriers and to optimize the LA treatment implementation should be designed.
Sections du résumé
BACKGROUND
BACKGROUND
Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers.
MATERIALS AND METHODS
METHODS
A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy. Three validate 4-items measures were used: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM).
RESULTS
RESULTS
Out of 61 ICONA centres, 38 (62%) completed the survey: 57.9% were academic centres, 42.1% were hospital-based. In total, 104 respondents were ID physicians (57.4%), 77 were nurses (42.5%); 4.5% of all PWH followed at the 38 centres started LAI CAB/RPV at time of study. Centres taking care of >1000 PWH reported 95% application of procedures for LA implementation, higher than other centres (P = 0.009). Mean score of AIM was (16.0, standard deviation, SD, 3.3), of IAM (16.0, SD 3.0) and FIM (16.0, SD 2.9). A linear correlation was found between AIM and the number of people with HIV who started LAI CAB/RPV (25-50 versus <25, coefficient of correlation [b] 2.57, 95%CI 0.91-4.60, P = 0.004), academic versus hospital-based centres (b -1.59, 95%CI -2.76-0.110044, P = 0.007) and the absence of preliminary systematic assessment of staff (b -1.98, 95%CI -3.31-0.65, P = 0.004). Implementation barriers were not significantly different according to the number of PWH/centre.
CONCLUSIONS
CONCLUSIONS
LAI CAB/RPV implementation was low, with a great variability according to centre size. Tailored and centre-specific interventions to address barriers and to optimize the LA treatment implementation should be designed.
Identifiants
pubmed: 39140512
pii: 7733466
doi: 10.1093/jac/dkae273
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gilead Sciences
Organisme : Janssen-Cilag
Organisme : MSD
Organisme : ViiV Healthcare
Investigateurs
A d'Arminio Monforte
(A)
A Antinori
(A)
S Antinori
(S)
A Castagna
(A)
R Cauda
(R)
G Di Perri
(G)
E Girardi
(E)
R Iardino
(R)
A Lazzarin
(A)
G C Marchetti
(GC)
C Mussini
(C)
E Quiros-Roldan
(E)
L Sarmati
(L)
B Suligoi
(B)
F von Schloesser
(F)
P Viale
(P)
A d'Arminio Monforte
(A)
A Antinori
(A)
A Castagna
(A)
F Ceccherini-Silberstein
(F)
A Cingolani
(A)
A Cozzi-Lepri
(A)
A Di Biagio
(A)
E Girardi
(E)
A Gori
(A)
S Lo Caputo
(S)
G Marchetti
(G)
F Maggiolo
(F)
C Mussini
(C)
M Puoti
(M)
C F Perno
(CF)
C Torti
(C)
A Antinori
(A)
F Bai
(F)
A Bandera
(A)
S Bonora
(S)
A Calcagno
(A)
D Canetti
(D)
A Castagna
(A)
F Ceccherini-Silberstein
(F)
A Cervo
(A)
A Cingolani
(A)
P Cinque
(P)
A Cozzi-Lepri
(A)
A d'Arminio Monforte
(A)
A Di Biagio
(A)
R Gagliardini
(R)
A Giacomelli
(A)
E Girardi
(E)
N Gianotti
(N)
A Gori
(A)
G Guaraldi
(G)
S Lanini
(S)
G Lapadula
(G)
M Lichtner
(M)
A Lai
(A)
S Lo Caputo
(S)
G Madeddu
(G)
F Maggiolo
(F)
V Malagnino
(V)
G Marchetti
(G)
A Mondi
(A)
V Mazzotta
(V)
C Mussini
(C)
S Nozza
(S)
C F Perno
(CF)
S Piconi
(S)
C Pinnetti
(C)
M Puoti
(M)
E Quiros Roldan
(E)
R Rossotti
(R)
S Rusconi
(S)
M M Santoro
(MM)
A Saracino
(A)
L Sarmati
(L)
V Spagnuolo
(V)
N Squillace
(N)
V Svicher
(V)
L Taramasso
(L)
C Torti
(C)
A Vergori
(A)
A Cozzi-Lepri
(A)
S De Benedittis
(S)
I Fanti
(I)
M Giotta
(M)
C Marelli
(C)
A Rodano'
(A)
A Tavelli
(A)
M Cernuschi
(M)
L Cosmaro
(L)
A Perziano
(A)
V Calvino
(V)
D Russo
(D)
M Farinella
(M)
N Policek
(N)
V L Del Negro
(VL)
M Augello
(M)
S Carrara
(S)
S Graziano
(S)
G Prota
(G)
S Truffa
(S)
D Vincenti
(D)
R Rovito
(R)
A Giacometti
(A)
A Costantini
(A)
V Barocci
(V)
A Saracino
(A)
C Santoro
(C)
E Milano
(E)
L Comi
(L)
C Suardi
(C)
P Viale
(P)
L Badia
(L)
S Cretella
(S)
E M Erne
(EM)
A Pieri
(A)
E Quiros Roldan
(E)
E Focà
(E)
C Minardi
(C)
B Menzaghi
(B)
C Abeli
(C)
L Chessa
(L)
F Pes
(F)
P Maggi
(P)
L Alessio
(L)
G Nunnari
(G)
B M Celesia
(BM)
J Vecchiet
(J)
K Falasca
(K)
A Pan
(A)
S Dal Zoppo
(S)
D Segala
(D)
M A Di Pietro
(MA)
C Costa
(C)
S Lo Caputo
(S)
S Ferrara
(S)
M Bassetti
(M)
E Pontali
(E)
S Blanchi
(S)
N Bobbio
(N)
G Mazzarello
(G)
M Lichtner
(M)
L Fondaco
(L)
S Piconi
(S)
C Molteni
(C)
S Rusconi
(S)
G Canavesi
(G)
G Pellicanò
(G)
G Marchetti
(G)
S Antinori
(S)
G Rizzardini
(G)
M Puoti
(M)
A Castagna
(A)
A Bandera
(A)
V Bono
(V)
M V Cossu
(MV)
A Giacomelli
(A)
R Lolatto
(R)
M C Moioli
(MC)
L Pezzati
(L)
S Diotallevi
(S)
C Tincati
(C)
C Mussini
(C)
M Menozzi
(M)
P Bonfanti
(P)
G Lapadula
(G)
V Sangiovanni
(V)
I Gentile
(I)
V Esposito
(V)
N Coppola
(N)
F M Fusco
(FM)
G Di Filippo
(G)
V Rizzo
(V)
N Sangiovanni
(N)
S Martini
(S)
A M Cattelan
(AM)
D Leoni
(D)
A Cascio
(A)
M Trizzino
(M)
D Francisci
(D)
E Schiaroli
(E)
G Parruti
(G)
F Sozio
(F)
D Messeri
(D)
S I Bonelli
(SI)
C Lazzaretti
(C)
R Corsini
(R)
A Antinori
(A)
R Cauda
(R)
C Mastroianni
(C)
L Sarmati
(L)
A Latini
(A)
A Cingolani
(A)
I Mastrorosa
(I)
S Lamonica
(S)
M Capozzi
(M)
M Camici
(M)
M Rivano Capparuccia
(M)
G Iaiani
(G)
C Stingone
(C)
L Gianserra
(L)
J Paulicelli
(J)
M M Plazzi
(MM)
G d'Ettore
(G)
M Fusto
(M)
I Coledan
(I)
G Madeddu
(G)
A De Vito
(A)
M Fabbiani
(M)
F Montagnani
(F)
A Franco
(A)
R Fontana Del Vecchio
(RF)
B M Pasticci
(BM)
C Di Giuli
(C)
G C Orofino
(GC)
G Calleri
(G)
G Di Perri
(G)
S Bonora
(S)
G Accardo
(G)
C Tascini
(C)
A Londero
(A)
G Battagin
(G)
S Nicolè
(S)
G Starnini
(G)
S Dell'Isola
(S)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.